We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.

U.S. markets closed

Opiant Pharmaceuticals, Inc. (OPNT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
8.46-0.42 (-4.73%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close8.88
Open8.99
Bid8.40 x 1000
Ask8.80 x 800
Day's Range8.31 - 8.99
52 Week Range6.79 - 15.68
Volume59,325
Avg. Volume25,781
Market Cap36.024M
Beta (5Y Monthly)0.78
PE Ratio (TTM)N/A
EPS (TTM)-0.03
Earnings DateNov 12, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
151% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • OPNT: Increased NARCAN Nasal Spray Sales Leads to Increased Royalties for Opiant…
    Zacks Small Cap Research

    OPNT: Increased NARCAN Nasal Spray Sales Leads to Increased Royalties for Opiant…

    By David Bautz, PhD NASDAQ:OPNT READ THE FULL OPNT RESEARCH REPORT Business Update Update on OPNT003 Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) is developing OPNT003, an intranasal (IN) formulation of nalmefene (a naltrexone derivative), which the company is developing as a long-lasting opioid antagonist for the treatment of opioid overdose. In 2018, Opiant received a $7.4 million grant from the

  • Benzinga

    Opiant Pharmaceuticals: Q3 Earnings Insights

    Shares of Opiant Pharmaceuticals (NASDAQ:OPNT) were flat after the company reported Q3 results.Quarterly Results Earnings per share fell 92.39% over the past year to $0.15, which beat the estimate of ($0.21).Revenue of $9,106,000 decreased by 55.88% from the same period last year, which beat the estimate of $7,760,000.Looking Ahead Earnings guidance hasn't been issued by the company for now.Opiant Pharmaceuticals hasn't issued any revenue guidance for the time being.Details Of The Call Date: Nov 12, 2020View more earnings on OPNTTime: 04:30 PMET Webcast URL: http://ir.opiant.com/Technicals Company's 52-week high was at $18.23Company's 52-week low was at $6.79Price action over last quarter: down 20.57%Company Description Opiant Pharmaceuticals Inc is a specialty pharmaceutical company operating in the US. It develops pharmacological treatments for substance use, addictive and eating disorders. The company has developed NARCAN, a Nasal Spray for treatment to reverse opioid overdoses. The company's pipeline includes medicines in development for Opioid Overdose Reversal (OOR), Alcohol Use Disorder (AUD), Opioid Use Disorder (OUD) and Acute Cannabinoid Overdose (ACO). The majority of the revenue is generated in the form of Royalty and licensing.See more from Benzinga * Click here for options trades from Benzinga * Earnings Scheduled For November 12, 2020 * 5 Value Stocks In The Healthcare Sector(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Opiant Pharmaceuticals Announces Third Quarter 2020 Financial Results and Corporate Update
    GlobeNewswire

    Opiant Pharmaceuticals Announces Third Quarter 2020 Financial Results and Corporate Update

    SANTA MONICA, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months ended September 30, 2020, and provided a corporate update. Recent highlights include: * OPNT003 nasal nalmefene for opioid overdose   -  Opiant to use Aptar Pharma’s Unit Dose System -  Upcoming FDA meeting in December to review Pharmacodynamic study in healthy volunteers and 505(b)(2) submission strategy -  Opiant continues to expect to file a New Drug Application by end of 2021 -  The Centers for Disease Control and Prevention reports an increase in fatal drug overdoses in the first three months of 2020 putting the U.S. on pace for record year of drug overdose deaths during coronavirus pandemic   * Q3 revenues of $9.1 million driven by NARCAN® Nasal Spray (“NARCAN®”) royalties   -  Recognized approximately $8.6 million in royalty revenue for Q3 2020 from approximately $88.8 million in net sales of NARCAN® Nasal Spray -  Projected royalties for the full-year 2020 raised from $26.2 million to approximately $28 million, based on Emergent Biosolutions (“EBS”) updated revenue guidance for NARCAN® sales of between $295 million and $315 million   * $31.1 million in cash and cash equivalentsCommenting on the quarter, Roger Crystal, M.D., President and Chief Executive Officer of Opiant, said:“Deaths from overdoses on opioids remain a crisis for communities across the United States, exacerbated by the COVID-19 pandemic. The determined deployment of opioid overdose rescue medication is essential to save lives. The trajectory of America’s opioid crisis, fueled by the availability of fentanyl and related synthetic opioids, underscores the need for stronger, longer-acting formulations of opioid antagonists. To this end, we made good progress this quarter with OPNT003 nasal nalmefene, our investigational treatment for opioid overdose. I am pleased we can now use Aptar Pharma’s Unit Dose System for OPNT003, which has been approved by the FDA with many other drug products, including NARCAN® Nasal Spray. Adding to the momentum, we will meet with the FDA in December to review the design of our pharmacodynamic study in healthy volunteers and our New Drug Application plan, which is on track to be submitted by the end of next year.”David O’Toole, Chief Financial Officer of Opiant, said:“Royalties from net sales of NARCAN® Nasal Spray continue to fortify our already strong balance sheet. EBS reported higher sales than expected this quarter and raised their NARCAN® revenue guidance for the year to a range of $295 million to $315 million. Based on this we have increased our projection of royalty revenue for the full year to approximately $28 million. We also now expect a cash balance at the end of 2020 of approximately $30 million.”Third Quarter 2020 Results For the three months ended September 30, 2020, Opiant recorded approximately $9.1 million in revenue, compared to approximately $20.6 million during the corresponding period of 2019. For the three months ended September 30, 2020, we recorded approximately $8.6 million of revenue from our license agreement with EBS for the sale of NARCAN®, compared to approximately $20.5 million in the same period of 2019 which included a final milestone payment of $13.5 million, as sales of NARCAN® Nasal Spray exceeded $200 million for 2019. Third quarter 2020 sales of NARCAN® were approximately $88.8 million, as reported by EBS.General and administrative expenses for the quarter were approximately $2.7 million, compared to $3.2 million for the same period in 2019. The $0.5 million decrease was primarily attributable to a decrease in legal and professional fees of approximately $0.8 million, partially offset by an increase in personnel and related expense of $0.3 million for the three months ended September 30, 2020 compared to the three months ended September 30, 2019. Research and development expenses were approximately $2.8 million, as compared to approximately $1.8 million in the third quarter of 2019. External development expense increased by $0.8 million and personnel and related expense increased by approximately $0.2 million during the three months ended September 30, 2020 compared to the three months ended September 30, 2019.Sales and marketing expenses were approximately $0.9 million, as compared to approximately $0.1 million in the third quarter of 2019. The $0.8 million increase was attributable to pre-commercialization efforts related to OPNT003 nasal nalmefene, which is under clinical development. Royalty expense for the second quarter was approximately $2 million compared to $4.9 million for the same period in 2019. Royalty expense is for payments that we make to our net profit partners on the royalties we received from the net sales of NARCAN®.Net income for the third quarter was approximately $0.7 million, or $0.17 per basic and $0.15 per diluted share, compared to net income of approximately $10.7 million, or $2.64 per basic and $1.97 per diluted share, for the comparable period of 2019.Financial Results for the Nine Months Ended September 30, 2020For the nine months ended September 30, 2020, Opiant recorded approximately $19.7 million in revenue, compared to approximately $32.9 million during the corresponding period of 2019. For the nine months ended September 30, 2020, we recognized approximately $19.1 million of revenue from our license agreement with EBS for the sale of NARCAN®, compared to approximately $30.4 million in the comparable period of 2019. The decrease in revenue of approximately $11.3 million was primarily attributable to a milestone payment of $13.5 million earned in the third quarter of 2019, as sales of NARCAN® exceeded $200 million for 2019, offset by an increase in royalties as a result of and increase in net sales of NARCAN® for the nine months ended September 30, 2020. Sales of NARCAN® for the nine months ended September 30, 2020, were approximately $233.8 million, as reported by EBS. General and administrative expenses for the nine months ended September 30, 2020, were approximately $8.1 million, compared to approximately $9.4 million in the comparable period of 2019. The decrease of $1.3 million was primarily due to a $1.5 million decrease in legal and professional fees, partially offset by a $0.2 million increase in personnel and related expense including stock based compensation for the nine months ended September 30, 2020 compared to the nine months ended September 30, 2019.Research and development expenses for the nine months ended September 30, 2020, were approximately $4.8 million, compared to approximately $7.0 million in the comparable period of 2019. The decrease of $2.2 million resulted from a decrease in third party clinical trial and development expense of $2.5 million, partially offset by an increase in personnel and related expense of $0.3 million.Sales and marketing expenses for the nine months ended September 30, 2020, were approximately $3.7 million, compared to $0.1 million during the same period 2019. For the nine months ended September 30, 2020 personnel and related expense including stock based compensation was $0.9 million, and $2.8 million was related to third party expenses for various pre-commercial activities including market research and assessments, and strategic planning.Royalty expenses were $4.3 million and $6.1 million during the nine months ended September 30, 2020 and 2019, respectively. Royalty expense is for payments that we make to our net profit partners on the royalties we received from the net sales of NARCAN®.Net loss for the nine months ended September 30, 2020, was approximately $1.2 million, or a loss of $0.28 per basic and diluted share, compared to a net income of approximately $10.6 million, or $2.64 per basic share and $1.98 per diluted share, for the comparable period of 2019.As of September 30, 2020, Opiant had cash and cash equivalents of $31.1 million, compared to approximately $31 million at December 31, 2019. The current cash balance does not include the full impact of the NIDA grant that we previously received of approximately $7.4 million or the BARDA contract of approximately $4.6 million.Conference Call Details: Thursday, November 12th at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time Toll Free: 877-407-0792 International: 201-689-8263 Conference ID: 13712206 Webcast: http://ir.opiant.com/ About Opiant Pharmaceuticals, Inc. Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose.For more information visit: www.opiant.com.Forward-Looking Statements This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements, and among other things, our ability to maintain cash balances and successfully commercialize or partner our product candidates currently under development. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "projects," "potential," or "continue" or the negative of such terms and other same terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. Additional factors that could materially affect actual results can be found in our filed quarterly reports on Form 10-Q and our annual report on Form 10-K for the year ended December 31, 2019, filed with the Securities and Exchange Commission on March 4, 2020, including under the caption titled "Risk Factors." These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law. Investor Relations Contacts:Ben Atkins VP of Corporate Communications and Investor Relations Batkins@opiant.com (310) 598-5410Dan Ferry Managing Director LifeSci Advisors, LLC Daniel@lifesciadvisors.com (617) 430-7576 Opiant Pharmaceuticals, Inc. Condensed Consolidated Balance Sheets (in thousands, except shares and per share amounts)         As of September 30, As of December 31,   2020 2019 Assets (unaudited)   Current Assets     Cash & cash equivalents $31,103  $30,981  Accounts receivable  8,613   7,218  Prepaid expenses and other current assets  862   1,056  Total Current Assets  40,578   39,255  Long-term Assets     Property and equipment, net of depreciation  202   243  Right of use assets - operating leases  397   769  Patents and patent applications, net of amortization  13   14  Other non-current assets  1,052   -  Total Assets $42,242  $40,281        Liabilities and stockholders' equity      Current Liabilities     Accounts payable and accrued expenses $2,553  $1,317  Accrued salaries & wages  1,435   1,238  Royalty payable  1,952   1,620  Deferred revenue  360   918  Operating leases - current  401   517  Total Current Liabilities  6,701   5,610  Long-Term Liabilities     Operating leases - long term  -   255  Total Long-Term Liabilities  -   255  Total Liabilities  6,701   5,865  Stockholders' equity     Common stock, $0.001 par value, 200,000,000 shares     authorized, 4,258,105 and 4,186,438 shares     issued and outstanding at September 30, 2020 and     December 31, 2019, respectively  4   4  Additional paid-in-capital  99,655   97,239  Foreign Currency Translation Adjustment  (115)  -  Accumulated deficit  (64,003)  (62,827) Total stockholders' equity  35,541   34,416  Total liabilities and stockholders' equity $42,242  $40,281  Opiant Pharmaceuticals Inc. Condensed Consolidated Statements of Operations (in thousands, except shares and per share amounts) (unaudited)             Three months ended Nine months ended   September 30, September 30,    2020   2019   2020   2019            Revenues         Royalty & licensing revenue $8,601  $20,494  $19,057  $30,368  Treatment investment revenue  -   -   -   644  Grant and contract revenue  505   147   644   1,838  Total Revenue  9,106   20,641   19,701   32,850  Operating expenses         General and administrative  2,729   3,211   8,138   9,389  Research and development  2,784   1,843   4,763   7,044  Sales and marketing  914   141   3,738   141  Royalty expense  1,952   4,851   4,289   6,099  Total operating expenses  8,379   10,046   20,928   22,673            Income (loss) from operations  727   10,595   (1,227)  10,177            Other income (expense)         Interest income  4   112   92   356  Gain (loss) on foreign exchange  (6)  (24)  (2)  (65) Total other income  (2)  88   90   291  Income (loss) before income taxes  725   10,683   (1,137)  10,468  Income tax (expense) benefit  -   -   (39)  57  Net income (loss) $725  $10,683  $(1,176) $10,525            Other comprehensive loss         Foreign currency translation adjustment  196   -   (115)  -  Total other comprehensive loss $921  $10,683  $(1,291) $10,525            Net income (loss) per common share         Basic $0.17  $2.64  $(0.28) $2.64  Diluted $0.15  $1.97  $(0.28) $1.98            Weighted-average common shares outstanding:        Basic  4,258,105   4,048,635   4,247,045   3,985,112  Diluted  4,847,211   5,422,345   4,247,045   5,310,157

  • ACCESSWIRE

    Opiant Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / November 12, 2020 / Opiant Pharmaceuticals, Inc.

  • Opiant Pharmaceuticals to Participate at the Jefferies 2020 Virtual London Healthcare Conference
    GlobeNewswire

    Opiant Pharmaceuticals to Participate at the Jefferies 2020 Virtual London Healthcare Conference

    SANTA MONICA, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, announced today that its Chief Executive Officer, Dr. Roger Crystal, is scheduled to present its pipeline at the Jefferies 2020 Virtual London Healthcare Conference on Thursday, November 19th, 2020, at 6:45 pm GMT. Management will be available for virtual one-on-one meetings throughout the conference taking place November 17-19, 2020. Please contact Jefferies sales representatives to participate in their investor conferences and to schedule a virtual one-on-one meeting with our management team. Investors, analysts, members of the media and the general public are invited to listen to an audio webcast of the presentation that can be accessed via the investor section of the Opiant website: www.opiant.com. A replay of the webcast will be available for 90 days following the event.About Opiant Pharmaceuticals, Inc. Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose. For more information, visit: www.opiant.com.Investor Relations Contacts:Ben Atkins VP of Corporate Communications and Investor Relations Batkins@opiant.com (310) 598-5410

  • Benzinga

    5 Value Stocks In The Healthcare Sector

    What are Value Stocks? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labeled as a value stock.The following stocks are considered to be notable value stocks in the healthcare sector: 1. Cronos Group (NASDAQ: CRON) - P/E: 2.52 2. Innoviva (NASDAQ: INVA) - P/E: 5.54 3. Tonix Pharmaceuticals (NASDAQ: TNXP) - P/E: 0.3 4. Opiant Pharmaceuticals (NASDAQ: OPNT) - P/E: 3.91 5. Catalyst Pharmaceuticals (NASDAQ: CPRX) - P/E: 7.62Most recently, Cronos Group reported earnings per share at -0.19, whereas in Q1 earnings per share sat at 0.2. Cronos Group does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Innoviva's earnings per share for Q3 sits at 0.26, whereas in Q2, they were at 0.69. Innoviva does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Tonix Pharmaceuticals has reported Q2 earnings per share at -0.23, which has increased by 37.84% compared to Q1, which was -0.37. Tonix Pharmaceuticals does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Opiant Pharmaceuticals saw an increase in earnings per share from -0.4 in Q1 to -0.05 now. Opiant Pharmaceuticals does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Catalyst Pharmaceuticals's earnings per share for Q2 sits at 0.09, whereas in Q1, they were at 0.1. Catalyst Pharmaceuticals does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.These 5 value stocks were selected by Benzinga Insights based on quantified analysis. While this methodical judgment process is not meant to make final decisions, our technology can give investors additional perception into the sector.See more from Benzinga * Click here for options trades from Benzinga * Clearwater Paper's Earnings: A Preview * AGCO's Earnings: A Preview(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Opiant Pharmaceuticals Partners with Aptar Pharma for Nasal Nalmefene Opioid Overdose Treatment
    GlobeNewswire

    Opiant Pharmaceuticals Partners with Aptar Pharma for Nasal Nalmefene Opioid Overdose Treatment

    * Agreement combines Opiant’s opioid antagonist OPNT003 nasal nalmefene, with Aptar's FDA-approved Unit Dose System delivery device * Reinforces Opiant’s continued commitment to innovative overdose treatment options as America’s opioid epidemic worsens * OPNT003 nasal nalmefene remains on track for NDA submission by the end of 2021 SANTA MONICA, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced it has entered into an agreement with drug delivery specialist Aptar Pharma (“Aptar”), for the development of OPNT003 nasal nalmefene for use in conjunction with Aptar’s Unit Dose System (UDS) for the treatment of opioid overdose.The Aptar UDS has been approved by the U.S. Food and Drug Administration (FDA) with multiple drug products marketed in the United States, including our internally developed and licensed NARCAN® Nasal Spray. “We believe our decision to partner with Aptar’s proven nasal delivery system represents a timely and strategic step forward for Opiant as we continue to advance OPNT003 as a potentially life-saving treatment for opioid overdose in the face of America’s worsening opioid epidemic,” said Roger Crystal, MD, President and Chief Executive Officer of Opiant.Opioids were involved in 51,574 overdose deaths in 2019 (71% of all drug overdose deaths) according to provisional data by the Centers for Disease Control and Prevention (CDC). Three out of four opioid-involved overdose deaths involve synthetic opioids, such as fentanyl, which is 50 times more potent than heroin. The COVID-19 coronavirus has worsened the outlook for 2020. The American Medical Association (AMA) recently cited that more than 40 states have reported rising opioid overdose-related fatalities amid the pandemic.OPNT003, nasal nalmefene, is being investigated to treat opioid overdose, which, if proven and ultimately approved, may be particularly useful in treating overdoses stemming from use of synthetic opioids, such as fentanyl. The development of OPNT003 is supported by a grant from the National Institutes of Health (NIH) and a contract from the Biological Advance Research and Development Agency (BARDA), who are interested in its potential as an antidote for use in a civilian mass casualty event. Opiant continues to anticipate filing a New Drug Application (NDA) in the United States for OPNT003 under a 505(b)(2) filing strategy by the end of 2021.In parallel, Opiant terminated an agreement with Aesica Queenborough Limited (which was ultimately acquired by Recipharm upon its acquisition of Consort Medical plc, and its Bespak Division, in 2019) to use its Unidose® Xtra device for OPNT003.  About Opiant Pharmaceuticals, Inc.  Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose. For more information visit: www.opiant.com.Forward-Looking Statements This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements, and among other things, our ability to maintain cash balances and successfully commercialize or partner our product candidates currently under development. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "projects," "potential," or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. Additional factors that could materially affect actual results can be found in our Form 10-K for the year ended December 31, 2019, filed with the Securities and Exchange Commission on March 4, 2020, including under the caption titled "Risk Factors."  These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.For Media and Investor Inquiries: Ben Atkins, Opiant (310) 598-5410 batkins@opiant.com

  • Opiant Pharmaceuticals to Report Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 12, 2020
    GlobeNewswire

    Opiant Pharmaceuticals to Report Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 12, 2020

    SANTA MONICA, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report its third quarter 2020 financial results after the financial markets close on Thursday November 12, 2020.   The Company’s management team is scheduled to host a conference call and webcast at 4:30 p.m. ET on Thursday November 12, 2020. To access the call, please dial 877-407-0792 in the U.S. or 201-689-8263 outside the U.S. and provide the conference ID number: 13712206. To access the live webcast, please go to the investors section of Opiant’s website at http://ir.opiant.com/. Following the live webcast, an archived version of the call will be available on the website.Thursday November 12 @ 4:30 pm ET Domestic: International: Conference ID: Webcast:877-407-0792 201-689-8263 13712206 http://ir.opiant.com/ About Opiant Pharmaceuticals, Inc.Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose. For more information visit: www.opiant.com.Investor Relations Contacts: Ben Atkins VP of Corporate Communications and Investor Relations batkins@opiant.com (310) 598-5410Dan Ferry Managing Director LifeSci Advisors, LLC daniel@lifesciadvisors.com (617) 430-7576

  • Benzinga

    A Look Into Healthcare Sector Value Stocks

    The Meaning Behind Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labeled as a value stock.Below is a list of notable value stocks in the healthcare sector: 1. Bio-Rad Laboratories (NYSE: BIO) - P/E: 7.96 2. Jaguar Health (NASDAQ: JAGX) - P/E: 0.02 3. Opiant Pharmaceuticals (NASDAQ: OPNT) - P/E: 5.01 4. OpGen (NASDAQ: OPGN) - P/E: 2.58 5. Karuna Therapeutics (NASDAQ: KRTX) - P/E: 0.17Bio-Rad Laboratories has reported Q2 earnings per share at 1.61, which has decreased by 15.71% compared to Q1, which was 1.91. Bio-Rad Laboratories does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Most recently, Jaguar Health reported earnings per share at -0.44, whereas in Q1 earnings per share sat at -0.56. Jaguar Health does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Opiant Pharmaceuticals has reported Q2 earnings per share at -0.05, which has increased by 87.5% compared to Q1, which was -0.4. Opiant Pharmaceuticals does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.This quarter, OpGen experienced a decrease in earnings per share, which was -0.43 in Q1 and is now -0.49. OpGen does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Karuna Therapeutics has reported Q2 earnings per share at -0.65, which has decreased by 96.97% compared to Q1, which was -0.33. Karuna Therapeutics does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.These 5 value stocks were selected by Benzinga Insights based on quantified analysis. While this methodical judgment process is not meant to make final decisions, our technology can give investors additional perception into the sector.See more from Benzinga * 5 Value Stocks In The Real Estate Sector * Benzinga's Top Upgrades, Downgrades For September 21, 2020 * How Does Northern Oil and Gas's Debt Look?(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • GlobeNewswire

    Opiant Pharmaceuticals to Participate at the 2020 Cantor Global Virtual Healthcare Conference

    SANTA MONICA, Calif., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, announced today that its Chief Executive Officer, Dr. Roger Crystal, is scheduled to participate in a fireside chat to discuss its pipeline of products for addiction and overdose  at the Cantor Global Virtual Healthcare Conference on Tuesday September 15th, 2020, at 2:40 pm EDT. Management will be available for virtual one-on-one meetings September 15th throughout the day. Please contact Cantor Fitzgerald sales representatives to participate in their investor conferences and to schedule a virtual one-on-one meeting with our management team. Investors, analysts, members of the media and the general public are invited to listen to an audio webcast of the presentation that can be accessed via the investor section of the Opiant website: www.opiant.com. A replay of the webcast will be available for 90 days following the event.About Opiant Pharmaceuticals, Inc. Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose. For more information visit: www.opiant.com.Investor Relations Contacts:Ben Atkins VP of Corporate Communications and Investor Relations Batkins@opiant.com (310) 598-5410Dan Ferry Managing Director LifeSci Advisors, LLC Daniel@lifesciadvisors.com (617) 430-7576Source: Opiant Pharmaceuticals, Inc.